The U.S. Food and Drug Administration (FDA) granted a supplemental efficacy approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) on November 24, 2025. This approval, designated as BLA 761381 S-5, was submitted by sponsor Bristol-Myers Squibb and pertains to the drug's efficacy profile.
Background
Nivolumab is an active pharmaceutical ingredient in several approved formulations, including Opdivo Qvantig, which combines nivolumab with hyaluronidase-nvhy. Supplemental applications for existing approved drugs, such as this one for Opdivo Qvantig, are submitted to the FDA to request changes to a product's approved uses. An efficacy-focused supplemental approval, as indicated here, typically signifies that the sponsor, Bristol-Myers Squibb, has provided new data supporting the drug's effectiveness for an expanded patient population, a new indication, or an updated treatment regimen. This process ensures that the drug's label accurately reflects the latest scientific evidence regarding its benefits.
What this means
This supplemental efficacy approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) on November 24, 2025, confirms that the FDA has reviewed and accepted new clinical data demonstrating the drug's effectiveness. For healthcare professionals, this may lead to updated prescribing information, potentially broadening the eligible patient population or refining the optimal use of Opdivo Qvantig in specific clinical scenarios. Patients and patient advocates can anticipate that this approval will offer new or improved treatment options, while researchers may find new avenues for investigation based on the data that supported this efficacy update. This type of approval underscores the ongoing development and refinement of established therapies to improve patient outcomes.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) through its public database of drug approvals. The approval for BLA 761381 S-5, concerning Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), was recorded on November 24, 2025, and is accessible on accessdata.fda.gov.